1
|
Liu Y, Cao Y, Zheng Y, Niu Y, Chen L, Chen X, Ma X, Li X, Zheng X, Feng W. Chemical Constituents with Anti-Proliferative Activity on Pulmonary Arterial Smooth Muscle Cells from the Roots of Anthriscus sylvestris (L.) Hoffm. Molecules 2024; 29:2547. [PMID: 38893423 PMCID: PMC11173479 DOI: 10.3390/molecules29112547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2024] [Revised: 05/25/2024] [Accepted: 05/27/2024] [Indexed: 06/21/2024] Open
Abstract
A chemical investigation of Anthriscus sylvestris roots led to the isolation and characterization of two new nitrogen-containing phenylpropanoids (1-2) and two new phenol glycosides (8-9), along with fifteen known analogues. Structure elucidation was based on HRESIMS, 1D and 2D NMR spectroscopy, and electronic circular dichroism (ECD). In addition, compounds 3, 6, 9-10, 12, and 17 exhibited inhibitory effects against the abnormal proliferation of pulmonary arterial smooth muscle cells with IC50 values ranging from 10.7 ± 0.6 to 57.1 ± 1.1 μM.
Collapse
Affiliation(s)
- Yanling Liu
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
| | - Yangang Cao
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
| | - Yajuan Zheng
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
| | - Ying Niu
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
| | - Lan Chen
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
| | - Xu Chen
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
| | - Xinyi Ma
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
| | - Xiangda Li
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
| | - Xiaoke Zheng
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
- Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Disease Diagnosis by Henan and Education Ministry of P. R. China, Zhengzhou 450046, China
| | - Weisheng Feng
- School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, China; (Y.L.); (Y.C.); (Y.Z.); (Y.N.); (L.C.); (X.C.); (X.M.); (X.L.); (X.Z.)
- The Engineering and Technology Center for Chinese Medicine Development of Henan Province China, Zhengzhou 450046, China
- Co-Construction Collaborative Innovation Center for Chinese Medicine and Respiratory Disease Diagnosis by Henan and Education Ministry of P. R. China, Zhengzhou 450046, China
| |
Collapse
|
2
|
Blanco I, Marquina M, Tura-Ceide O, Ferrer E, Ramírez AM, Lopez-Meseguer M, Callejo M, Perez-Vizcaino F, Peinado VI, Barberà JA. Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension. Front Pharmacol 2023; 14:1145994. [PMID: 37188265 PMCID: PMC10176173 DOI: 10.3389/fphar.2023.1145994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 04/11/2023] [Indexed: 05/17/2023] Open
Abstract
Background: Imbalance between cell proliferation and apoptosis underlies the development of pulmonary arterial hypertension (PAH). Current vasodilator treatment of PAH does not target the uncontrolled proliferative process in pulmonary arteries. Proteins involved in the apoptosis pathway may play a role in PAH and their inhibition might represent a potential therapeutic target. Survivin is a member of the apoptosis inhibitor protein family involved in cell proliferation. Objectives: This study aimed to explore the potential role of survivin in the pathogenesis of PAH and the effects of its inhibition. Methods: In SU5416/hypoxia-induced PAH mice we assessed the expression of survivin by immunohistochemistry, western-blot analysis, and RT-PCR; the expression of proliferation-related genes (Bcl2 and Mki67); and the effects of the survivin inhibitor YM155. In explanted lungs from patients with PAH we assessed the expression of survivin, BCL2 and MKI67. Results: SU5416/hypoxia mice showed increased expression of survivin in pulmonary arteries and lung tissue extract, and upregulation of survivin, Bcl2 and Mki67 genes. Treatment with YM155 reduced right ventricle (RV) systolic pressure, RV thickness, pulmonary vascular remodeling, and the expression of survivin, Bcl2, and Mki67 to values similar to those in control animals. Lungs of patients with PAH also showed increased expression of survivin in pulmonary arteries and lung extract, and also that of BCL2 and MKI67 genes, compared with control lungs. Conclusion: We conclude that survivin might be involved in the pathogenesis of PAH and that its inhibition with YM155 might represent a novel therapeutic approach that warrants further evaluation.
Collapse
Affiliation(s)
- Isabel Blanco
- Department of Pulmonary Medicine, Hospital Clínic-University of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain
- *Correspondence: Isabel Blanco,
| | - Maribel Marquina
- Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain
| | - Olga Tura-Ceide
- Department of Pulmonary Medicine, Hospital Clínic-University of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain
- Biomedical Research Institute-IDIBGI, Girona, Spain
| | - Elisabet Ferrer
- Department of Pulmonary Medicine, Hospital Clínic-University of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom
| | - Ana M. Ramírez
- Department of Pulmonary Medicine, Hospital Clínic-University of Barcelona, Barcelona, Spain
| | | | - Maria Callejo
- Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain
- Departament of Pharmacology and Toxicology, School of Medicine, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Universidad Complutense de Madrid, Madrid, Spain
| | - Francisco Perez-Vizcaino
- Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain
- Departament of Pharmacology and Toxicology, School of Medicine, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Universidad Complutense de Madrid, Madrid, Spain
| | - Victor Ivo Peinado
- Department of Pulmonary Medicine, Hospital Clínic-University of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain
- Department of Experimental Pathology, Institut d’Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Barcelona, Spain
| | - Joan Albert Barberà
- Department of Pulmonary Medicine, Hospital Clínic-University of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid, Spain
| |
Collapse
|
3
|
Chen G, Chen S, Di X, He S, Liu Y, Qu R, Luo Y, Liu Y, Yang L. Survivin knockdown alleviates pathological hydrostatic pressure-induced bladder smooth muscle cell dysfunction and BOO-induced bladder remodeling via autophagy. Front Cell Dev Biol 2022; 10:999547. [PMID: 36393846 PMCID: PMC9649584 DOI: 10.3389/fcell.2022.999547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2022] [Accepted: 10/10/2022] [Indexed: 09/05/2023] Open
Abstract
Aim: Bladder outlet obstruction (BOO) leads to bladder wall remodeling accompanying the progression from inflammation to fibrosis where pathological hydrostatic pressure (HP)-induced alteration of bladder smooth muscle cells (BSMCs) hypertrophic and excessive extracellular matrix (ECM) deposition play a pivotal role. Recently, we have predicted survivin (BIRC5) as a potential hub gene that might be critical during bladder fibrosis by bioinformatics analyses from rat BOO bladder, but its function during BOO progression remains unknown. Here, we investigated the role of survivin protein on bladder dysfunction of BOO both in vitro and in vivo. Methods: Sprague-Dawley female rats were divided into three groups: control group, BOO group, and BOO followed by the treatment with YM155 group. Bladder morphology and function were evaluated by Masson staining and urodynamic testing. To elucidate the underlying mechanism, hBSMCs were subjected to pathological HP of 200 cm H2O and co-cultured with the presence or absence of survivin siRNA and/or autophagy inhibitor 3-MA. Autophagy was evaluated by the detection of Beclin1 and LC3B-II expression, proliferation was conducted by the EdU analysis and PCNA expression, and fibrosis was assessed by the examination of Col 1 and Fn expression. Results: BOO led to a gradual alteration of hypertrophy and fibrosis of the bladder, and subsequently induced bladder dysfunction accompanied by increased survivin expression, while these histological and function changes were attenuated by the treatment with YM155. HP significantly increased survivin expression, upregulated Col1 and Fn expression, enhanced proliferation, and downregulated autophagy markers, but these changes were partially abolished by survivin siRNA treatment, which was consistent with the results of the BOO rat experiment. In addition, the anti-fibrotic and anti-proliferative effects of the survivin siRNA treatment on hBSMCs were diminished after the inhibition of autophagy by the treatment with 3-MA. Conclusion: In summary, the upregulation of survivin increased cell proliferation and fibrotic protein expression of hBSMC and drove the onset of bladder remodeling through autophagy during BOO. Targeting survivin in pathological hBSMCs could be a promising way to anti-fibrotic therapeutic approach in bladder remodeling secondary to BOO.
Collapse
Affiliation(s)
- Guo Chen
- Department of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
- Laboratory of Reconstructive Urology, West China Hospital, Institute of Urology, Sichuan University, Chengdu, China
| | - Shuang Chen
- Laboratory of Reconstructive Urology, West China Hospital, Institute of Urology, Sichuan University, Chengdu, China
| | - Xingpeng Di
- Laboratory of Reconstructive Urology, West China Hospital, Institute of Urology, Sichuan University, Chengdu, China
| | - Shengyin He
- Department of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
| | - Yugao Liu
- Department of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
| | - Rui Qu
- Department of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
| | - Yi Luo
- Department of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
| | - Yuebai Liu
- Department of Education and Training, Sichuan Cancer Hospital, Chengdu, China
| | - Luo Yang
- Department of Urology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
| |
Collapse
|